Veradermics to Hold Conference Call to Discuss Topline Results from Phase 2/3 ‘302’ Study of VDPHL01 in Males with Mild-to-Moderate Pattern Hair Loss
Go back to Veradermics to Hold Conference Call to Discuss Topline Results from Phase 2/3 ‘302’ Study of VDPHL01 in Males with Mild-to-Moderate Pattern Hair Loss| (NYSE: MANE) | Delayed: 103.60 +0.81 (0.79%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $102.79 | 52 Week High | $ | |||
| Open | $100.49 | 52 Week Low | $ | |||
| Day High | $107.32 | P/E | N/A | |||
| Day Low | $100.49 | EPS | $ | |||
| Volume | 615,941 | |||||
